<DOC>
	<DOCNO>NCT01746862</DOCNO>
	<brief_summary>This open-label , multi-center , randomize , two-arm parallel , no-treatment group control ( first 6 month ) , Phase 3 study child ISS . The subject treat 0.067 milligram/kilogram/day ( mg/kg/day ) Saizen® , weight base dose , 12 month ( 12 month treatment test group , 6 month treatment 6 month treatment control group ) .</brief_summary>
	<brief_title>A Phase 3 Study Evaluate Safety Efficacy Saizen® Children With Idiopathic Short Stature ( ISS )</brief_title>
	<detailed_description />
	<mesh_term>Dwarfism</mesh_term>
	<criteria>Age great equal 5 year Prepubertal ; testicular volume le 4 milliliter ( male ) breast Stage 1 ( female ) The official record height ( example record measure hospital school ) previous 6 month precede inclusion study ( selfmeasurement height home consider valid record ) Height le equal 3rd percentile compare sex , age Peak serum growth hormone ( GH ) great 10 microgram per liter ( mcg/L ) GH stimulation test ( result peak serum GH great 10 mcg/L GH stimulation test within 1 year use instead ) Naive GH therapy Normal birth weight ( great equal 3rd percentile compare sex ) Normal thyroid function Normal karyotype girl Written inform consent parent/guardian Written inform consent subject speaks , understand , read , write Korean Bone age less 10 year boys less 9 year girl , whose difference bone chronological age 3 year Puberty development ( Tanner stage great equal 2 ) Skeletal dysplasia abnormal body proportion Chronic systemic illness Dysmorphic syndrome Growth Hormone Deficiency Small Gestational Age ( SGA ) Current medication Attention deficit hyperactivity disorder ( ADHD ) hyperactivity disorder Current medication drug may influence secretion action growth hormone ( estrogen , androgen , anabolic steroid , corticosteroid , thyroxine , aromatase inhibitor ) Diabetes mellitus Kidney transplantation Acute critical illness , include complication follow open heart surgery , abdominal surgery multiple accidental trauma Acute respiratory failure Malignancy previous therapy malignancy Known hypersensitivity somatotropin excipients include cresol glycerol Closed epiphysis , progression recurrence underlie intracranial tumor , chronic renal disease Endocrinologic metabolic disorder PraderWilli syndrome ; RusselSilver syndrome ; Seckel syndrome ; Down syndrome ; Cushing syndrome ; Noonan syndrome ; short stature cause chromosomal abnormality The disorder explain short stature psychiatric disorder , nutritional disorder , chronic debilitating disease Participation another clinical trial within past 3 month Status legal incapacity limited legal capacity parent legal guardian</criteria>
	<gender>All</gender>
	<minimum_age>5 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Saizen®</keyword>
	<keyword>Recombinant human growth hormone ( r-hGH )</keyword>
	<keyword>Idiopathic short stature</keyword>
	<keyword>Height velocity</keyword>
	<keyword>Bone age</keyword>
</DOC>